首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 醫療設備 > 導管 > 全球塗藥支架•裸支架•其他冠狀動脈支架市場:2008年至2017年
產業/市場分類
醫療設備 (3974)
內視鏡檢查設備 (113)
分子呈像/呈影劑 (29)
心血管設備 (244)
可拋式醫學設備 (83)
核子醫學 (75)
病患監測 (343)
眼科設備 (100)
傷口護理 (87)
超音波 (49)
齒科設備 (172)
導管 (198)
整形外科 (329)
醫學影像診斷 (399)
體外診斷設備 (387)
CT/MRI/X光 (142)
e保健 (309)
市場調查報告書

全球塗藥支架•裸支架•其他冠狀動脈支架市場:2008年至2017年

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

出版商 MedMarket Diligence
出版日期 2009年05月 商品編碼 84696
內容資訊 英文 290 pages, 61 Exhibits, 76 Company Profiles
價格
US $ 1950 Hard Copy
US $ 1950 PDF by E-mail (Single User License)
US $ 2150 PDF by E-mail (Single User License) & Hard Copy
US $ 3450 PDF by E-mail ( Site License)
US $ 4450 PDF by E-mail (Global Site License)


全球塗藥支架•裸支架•其他冠狀動脈支架市場:2008年至2017年 是由出版商MedMarket Diligence在2009年05月所出版的。 這份英文市場調查報告書包含290 pages, 61 Exhibits, 76 Company Profiles 價格從美金1950起跳。

簡介

此報告書對於全球使用在冠狀動脈疾病治療的冠狀動脈支架市場進行調查分析,並彙整了各種替代治療技術概要、患者人口、各種產品與技術的開發動向、全球以及主要地區的市場規模、市場成長預測、主要企業的市場佔有率、簡介等。報告書之內容摘要如下所示。

摘要

第1章 臨床背景

  • 符合支架移植的冠狀動脈疾病
    • 急性閉鎖
    • 血管成型後再次發生狹窄
  • 糖尿病
  • 支架留置與CABG•血管成型術
  • 冠狀動脈硬化症的替代性治療
    • 含/不含支架留置的血管成型術
    • 粥狀瘤切除術
    • 冠狀動脈繞道術(CABG)
    • 經心肌血管重建術(TMR)
    • 基因治療
    • HDL治療
    • 奈米粒子•其他藥劑
    • 塗藥氣球導管
  • 冠狀動脈支架術的件數
  • 冠狀動脈支架術的相關合併症

第2章 產品•技術

  • 冠狀動脈用支架材料
  • 支架的各種形狀與其影響
  • 冠狀動脈支架的FDA認可
  • 冠狀動脈支架的償還
  • 裸金屬支架
  • 塗藥支架
  • 生體吸收性支架
  • 其他支架
  • 法律程序
  • 主要臨床實驗

第3章 市場•市場預測•企業的市場佔有率

  • 全球
    • 裸金屬支架(BMS)
    • 塗藥支架(DES)
    • 生體吸收性支架
  • 美國
    • BMS
    • DES
    • 生體吸收性支架
  • 歐洲
  • 亞洲太平洋
  • 其他

第4章 企業簡介

附錄

目錄

Abstract

This report details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

Methodology

MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources (annual reports, SEC 10K reports, company literature, others) on products and technologies on the market and under development. Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data (third party reports, brokerage reports, federal/state/international datasets) are used to corroborate and support assessments and projections. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND

  • 1.1 Cardiovascular Disorders Applicable for Stent Implantation
    • 1.1.1 Acute Closure
    • 1.1.2 Restenosis After Angioplasty
  • 1.2 Risk Factors for Coronary Heart Disease
  • 1.3 Stenting vs. CABG and Angioplasty
  • 1.4 Alternative Therapies for Coronary Atherosclerosis
    • 1.4.1 Angioplasty With or Without Stenting
    • 1.4.2 Atherectomy
    • 1.4.3 Coronary Artery Bypass Graft (CABG)
      • 1.4.3.1 Open CABG
      • 1.4.3.2 Off-Pump Coronary Artery Bypass (OPCAB)
      • 1.4.3.3 MIDCAB (Minimally Invasive Direct Coronary Bypass)
      • 1.4.3.4 RACAB (Robotic Assisted Coronary Artery Bypass)
      • 1.4.3.5 Other Forms of CABG
    • 1.4.4 Transmyocardial Laser Revascularization (TMR)
    • 1.4.5 Genetic Therapies
    • 1.4.6 HDL Therapy
    • 1.4.7 Drug-Eluting Balloons
    • 1.4.8 Nanoparticles and Other Agents
  • 1.5 Incidence and Prevalence of Cardiovascular Stenting Procedures
  • 1.6 Complications Related to Cardiovascular Stents

SECTION 2: PRODUCTS, TECHNOLOGIES

  • 2.1 Materials Used in Cardiovascular Stents
  • 2.2 Various Stent Shapes and Resulting Impact
  • 2.3 FDA Approval of Cardiovascular Stents
  • 2.4 Reimbursement of Drug-Eluting Stents
  • 2.5 Bare Metal Stents
  • 2.6 Drug-Eluting Stents
    • 2.6.1 Abbott Vascular
    • 2.6.2 Boston Scientific
    • 2.6.3 Johnson & Johnson/Cordis
    • 2.6.4 Medtronic
    • 2.6.5 Other Drug-Eluting Stent Companies
  • 2.7 Bioabsorbable Stents
  • 2.8 Other Types of Stents
  • 2.9 Legal Proceedings
  • 2.10 Key Clinical Trials
    • 2.10.1 HORIZONS AMI
    • 2.10.2 SYNTAX
    • 2.10.3 SPIRIT
    • 2.10.4 COURAGE
    • 2.10.5 PROTECT
    • 2.10.6 ENDEAVOR
    • 2.10.7 FAME
    • 2.10.8 SORT OUT III
    • 2.10.9 DAPT
    • 2.10.10 ZEST

SECTION 3: MARKETS FORECASTS AND COMPETITOR SHARES

  • 3.1 Worldwide Market for Coronary Stents
    • 3.1.1 Worldwide Market for Drug-Eluting Coronary Stents
    • 3.1.2 Worldwide Market for Bare Metal Coronary Stents
    • 3.1.3 Worldwide Market for Absorbable Coronary Stents
  • 3.2 U.S. Market for Coronary Stents
    • 3.2.1 U.S. Market for Drug-Eluting Coronary Stents
    • 3.2.2 U.S. Market for Bare Metal Coronary Stents
    • 3.2.3 U.S. Market for Absorbable Coronary Stents
  • 3.3 European Market for Coronary Stents
    • 3.3.1 European Market for Drug-Eluting Coronary Stents
    • 3.3.2 European Market for Bare Metal Coronary Stents
    • 3.3.3 European Market for Absorbable Coronary Stents
  • 3.4 Asia/Pacific Market for Coronary Stents
    • 3.4.1 Asia/Pacific Market for Drug-Eluting Coronary Stents
    • 3.4.2 Asia/Pacific Market for Bare Metal Coronary Stents
    • 3.4.3 Asia/Pacific Market for Absorbable Coronary Stents
  • 3.5 Rest of World (ROW) Market for Coronary Stents
    • 3.5.1 ROW Market for Drug-Eluting Coronary Stents
    • 3.5.2 ROW Market for Bare Metal Coronary Stents
    • 3.5.3 ROW Market for Absorbable Coronary Stents

SECTION 4: COMPANY PROFILES

  • 4.1 Aachen Resonance GmbH
  • 4.2 Abbott Vascular
  • 4.3 AdvanSource Biomaterials Corporation
  • 4.4 Aeon Bioscience
  • 4.5 Allvivo Vascular, Inc.
  • 4.6 Amaranth Medical, Inc.
  • 4.7 amg International GmbH
  • 4.8 Arterial Remodeling Technologies (ART)
  • 4.9 Atrium Medical
  • 4.10 Avantec Vascular
  • 4.11 B. Braun Melsungen
  • 4.12 Balton Ltd.
  • 4.13 Bioabsorbable Therapeutics, Inc.
  • 4.14 Bioring SA
  • 4.15 Biosensors International
  • 4.16 Biotronik
  • 4.17 Blue Medical Devices B.V.
  • 4.18 Boston Scientific
  • 4.19 Caliber Therapeutics
  • 4.20 Cappella Inc.
  • 4.21 CardioMind, Inc.
  • 4.22 CeloNova BioSciences, Inc.
  • 4.23 CID S.r.l. (Formerly Sorin Vascular Therapy)
  • 4.24 Cinvention AG (Formerly Blue Membranes)
  • 4.25 CorNova
  • 4.26 CV Therapeutics/Gilead Inc.
  • 4.27 Devax
  • 4.28 DISA Vascular
  • 4.29 Elixir Medical Corp.
  • 4.30 Estracure Inc.
  • 4.31 eucatech AG
  • 4.32 Genesis Technologies, LLC
  • 4.33 Global Therapeutics (Cook Medical)
  • 4.34 Hexacath
  • 4.35 ICON Interventional (Formerly ICON Medical Corp.)
  • 4.36 InspireMD
  • 4.37 InTek Technology
  • 4.38 Invatec s.r.l.
  • 4.39 ITGI Medical Ltd.
  • 4.40 Johnson & Johnson
    • 4.40.1 Cordis
    • 4.40.2 Conor Medsystems (J&J)
  • 4.41 JW Medical Systems / Biosensors International
  • 4.42 Kaneka Corporation
  • 4.43 Kyoto Medical Planning Co., Ltd.
  • 4.44 Lepu Medical
  • 4.45 Lutonix, Inc.
  • 4.46 Medinol/ARIAD Pharmaceuticals
  • 4.47 Medlogics Device Corporation (MDC)
  • 4.48 Medtronic Vascular
  • 4.49 Miami Cardiovascular Innovations
  • 4.50 Micell Technologies
  • 4.51 MicroPort Scientific Corporation
  • 4.52 Minvasys
  • 4.53 MIV Therapeutics
  • 4.54 mNEMOSCIENCE GmbH
  • 4.55 MoBeta, Inc.
  • 4.56 NanoInterventions, LLC
  • 4.57 Neovasc, Inc.
  • 4.58 Nexeon MedSystems, Inc.
  • 4.59 Opto Circuits (India) Ltd.
    • 4.59.1 EuroCor GmbH
  • 4.60 OrbusNeich
  • 4.61 Palmaz Scientific, Inc.
  • 4.62 Picarus NV
  • 4.63 Possis Medical (Bayer)
  • 4.64 Prescient Medical
  • 4.65 Relisys Medical Devices
  • 4.66 REVA Medical
  • 4.67 Sahajanand Medical Technologies
  • 4.68 Stentys SAS
  • 4.69 Terumo
  • 4.70 Translumina
  • 4.71 TriReme Medical
  • 4.72 Tryton Medical
  • 4.73 Vascular Concepts
  • 4.74 VasoTech, Inc.
  • 4.75 X-Cell Medical
  • 4.76 Xtent, Inc. (ceasing operations)

APPENDIX I: SELECTED CLINICAL TRIALS

  • ABSORB
  • ARRIVE II Registry
  • ARTS
  • AXXESS PLUS
  • BASKET
  • BBC ONE
  • CARE
  • COREL
  • COSTAR
  • COURAGE
  • CUSTOM
  • DEScover Registry
  • DIRECT
  • DIVERGE
  • e-HEALING
  • EASTER Registry
  • ENDEAVOR
  • ETHOS
  • EuroSTAR
  • EVENT Registry
  • FAME
  • GENESIS
  • FOCUS
  • HEALING
  • HORIZONS-AMI
  • ISAR, ISAR-TEST-2
  • LONG DES
  • NOBLESS
  • NOBORI
  • NORDIC
  • OLYMPIA Registry
  • PASSION
  • PREPARE
  • PROGRESS
  • RESOLUTE
  • RESORB
  • REWARD Registries
  • SERIES
  • SIMPLE Registries
  • SIRIUS, E-SIRIUS, C-SIRIUS
  • SORT-OUT III
  • SPIRIT
  • STEALTH
  • STEMI
  • STENT Registry
  • SVELT
  • TAXUS
  • TYPHOON
  • ZEST-AMI
  • ZOMAXX

APPENDIX II: COMPANY DIRECTORY

List of Exhibits

  • Exhibit ES-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
  • Exhibit ES-2: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
  • Exhibit ES-3: Potential Complications Related to Implantation of Cardiovascular Stents
  • Exhibit ES-4: Types of Coronary Stents and Selected Anti-Restenosis Devices
  • Exhibit ES-5: Worldwide DES Market by Company, Calendar 4th Quarter, 2008
  • Exhibit ES-6: Worldwide Market for Coronary Stents, by Type, Revenue Forecast, 2008 - 2017
  • Exhibit ES-7: Worldwide Market for Drug-Eluting Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
  • Exhibit ES-8: Worldwide Market for Bare Metal Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
  • Exhibit ES-9: Worldwide Market for Absorbable Coronary Stents, by Region, Revenue, 2012 - 2017
  • Exhibit 1-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
  • Exhibit 1-2: International Death Rates Per 100,000 Population for Total Cardiovascular Disease and Coronary Heart Disease for the Top 20 Countries
  • Exhibit 1-3: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
  • Exhibit 1-4: Drug-Eluting Balloon Catheters
  • Exhibit 1-5: Estimated Inpatient Cardiovascular Procedures, U.S., 2006 (000)
  • Exhibit 1-6: Number of Discharges, Coronary Atherosclerosis, U.S.
  • Exhibit 1-7: National Healthcare Cost and Utilization Project Statistics: Mean Charges and In-Hospital Death Rates for Various Cardiovascular Procedures, U.S.
  • Exhibit 1-8: Total Number of Cardiac Revascularization Discharges and Mean Charges, U.S., 1993 - 2006
  • Exhibit 1-9: Total Number of Discharges for PCI Procedures with Non-Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
  • Exhibit 1-10: Total Number of Discharges for PCI Procedures with Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
  • Exhibit 1-11: Total Number of Discharges for PCI Procedures with Non-Drug and Drug-Eluting Stent Discharges and Mean Charges, U.S., 2002 - 2006
  • Exhibit 2-1: Competitors in the Market for Bare Metal Stents
  • Exhibit 2-2: Competitors in the Market for Drug-Eluting Stents
  • Exhibit 2-3: Competitors in the Market for Bioresorbable Stents
  • Exhibit 2-4: Competitors in the Market for Novel Stent Technologies
  • Exhibit 3-1: Worldwide Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-2: Worldwide Drug-Eluting Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-3: Revenues for Leading Drug-Eluting Stent Market Competitors, Worldwide, 2008
  • Exhibit 3-4: Worldwide Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-5: Worldwide Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 3-6: U.S. Market for Coronary Stents, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-7: U.S. Coronary Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-8: Revenues for Leading Drug-Eluting Stent Market Competitors, United States, 2008
  • Exhibit 3-9: U.S. Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-10: U.S. Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
  • Exhibit 3-11: European Coronary Stent Market, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-12: European Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-13: European Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-14: European Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
  • Exhibit 3-15: Asia/Pacific Market Forecasts for Coronary Stents, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-16: Asia/Pacific Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-17: Asia/Pacific Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-18: Asia/Pacific Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 3-19: Rest of World Coronary Stent Market, by Type, Revenue Forecast 2008-2017
  • Exhibit 3-20: Rest of World Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-21: Rest of World Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-22: Rest of World Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 4-1: AdvanSource Biomaterials Third Quarter Financial Results ($000s)
  • Exhibit 4-2: Medtronic Financial Data, Third Quarter 2009 ($millions)
  • Exhibit 4-3: Medtronic' s Coronary Stent Revenues, FY 2008 & 2009 ($millions)
  • Exhibit 4-4: Xtent Financial Data, Fourth-Quarter 2008 ($millions)
Back to Top